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ABSTRACT
Type 1 diabetes mellitus (T1DM) is an endocrine disorder that continues to afflict a growing
proportion of the U.S. population. Characterized by an autoimmune attack on the pancreatic [beta] cells
that leads to their destruction, T1DM develops from absolute insulin deficiency resulting in chronic
hyperglycemia. Although the disease requires lifelong insulin therapy and confers enhanced risk for
long-term complications, the mechanism of [beta] cell death remains unclear. Fas receptor signaling is
critical among cells of hematopoietic origin for its role in immune homeostasis and mediation of target
cell death. Fas receptor-ligand interactions might also have a role in [beta] cell death leading to the
development of T1DM; pro-inflammatory cytokines released from islet leukocytes can induce Fas
receptor to the [beta] cell surface, and systemic loss-of-function mutations in Fas receptor and Fas
ligand (FasL) abrogate disease in spontaneous diabetes-prone mice. However, systemic deficiency in Fas
and FasL causes an alteration in the T cell repertoire that prevents diabetes, and thus cannot be
attributed to absence of Fas [beta] cell signaling. Moreover, the use of distinct Fas mutations and
transgenic models that produce dissimilar mechanisms of [beta] cell death leads to conflicting results
reported in the scientific literature. Recent evidence using transgenic mouse models of diabetes has
indicated a role for Fas in the insulitic phase but not the effector phase of [beta] cell death, while other
studies have suggested that alteration of the T cell repertoire by Fas signaling is a causal factor in the
autoimmune [beta] cell attack. Furthermore, ectopically-expressed FasL is a potential therapeutic tool
for protection of islet transplants by its known ability to provide immune privilege in some tissues. This
literature review collectively presents the diverse roles for Fas signaling in [beta] cell death and provides
insight into why conflicting conclusions regarding Fas signaling currently exist. Thus, the goal of this
literature review is to enable investigators interested in Fas-mediated signaling in the pancreatic [beta]
cell to choose an appropriate model system for study design that ideally will translate to therapeutic
interventions for T1DM.
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CHAPTER I
General Overview
I. Characterization of Diabetes Mellitus
Diabetes mellitus is the umbrella term for the most common endocrine disorder affecting
people in the United States. The rise in prevalence of this disease is accompanied by numerous studies
devoted to understanding the molecular mechanism of action with the hope of generating novel
therapeutic interventions. A much larger proportion of people now know at least one individual affected
by diabetes and are dedicated to increasing awareness in an effort to gain funding for diabetes research.
To appreciate the implications of living with diabetes and the critical need for effective therapies, it is
important to understand the clinical characterization and pathogenesis of the disease.
Two major forms of diabetes exist: These are Type 1 (T1DM) and Type 2 (T2DM) and they share
a common phenotype of overall losses in functional β-cell mass leading to hyperglycemia. Diminution of
the pancreatic β-cell mass results in insulin deficiency. Insulin is a hormone secreted by β-cells of the
pancreatic islet of Langerhans, and is critical to blood glucose homeostasis via its ability to promote
cellular glucose entry and exit from the circulation. Insulin secretion is controlled by a number of
different fuel substrates, with glucose providing the biggest overall effect. Glucose-stimulated insulin
secretion (GSIS) is directed by a complex interaction of multiple metabolic pathways that begins with βcell glucose entry and metabolism, and concludes with exocytosis of insulin-containing granules [1]. Loss
of endogenous insulin signaling leads to alterations in fuel metabolism in a variety of tissues, and
drastically impacts blood glucose homeostasis; the clinical manifestation is development of diabetes
mellitus.
T2DM is the most prevalent form of diabetes, accounting for over 90% of total cases [2].
Although most commonly diagnosed in adults over 40 years of age, T2DM incidence continues to
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increase in young adults and adolescents. Development of the disorder is initiated with insulin
resistance, whereby a decrease in insulin-mediated glucose uptake causes the pancreatic β-cell to
respond by expanding its mass and increasing insulin secretion. However, once the β-cell can no longer
expand or secrete sufficient amounts of insulin to match the rising insulin demands, occurrence of β-cell
deficiency leads to impaired glucose tolerance and overt T2DM [3]. A number of factors are associated
with increased risk for development of T2DM, and include an individual’s genetic background as well as
environmental factors. For example, visceral fat accumulation has progressively increased among the US
population in parallel with T2DM incidence. Although insulin resistance is the initial step in development
of T2DM, only about one-third of obese insulin-resistant individuals progress to overt T2DM; only when
the β-cell can no longer meet the body’s insulin demands do chronic hyperglycemia and diabetes
develop.
Gestational diabetes mellitus (GDM) is a form of diabetes that is significantly less prevalent than
either T1DM or T2DM, affecting approximately 7% of pregnant women, but whose pathogenesis is
similar to T2DM. GDM is most commonly diagnosed in the third trimester of gestation and can be
treated with dietary intervention and exercise, although insulin therapy may be required for more
severe cases. Although the disorder often resolves at birth, women treated for GDM are at a
significantly increased risk for development of T2DM, and to a much lesser extent T1DM. Maternal GDM
increases the offspring risk for adverse outcomes, most notably macrosomia [4]; intrauterine exposure
to hyperglycemia has also been suggested to create metabolic memory that results in T2DM
development later in life. Indeed, children born to mothers with GDM have a significantly enhanced risk
for development of T2DM relative to children born to mothers who do not carry the disorder.
T1DM is less prevalent than T2DM, yet currently affects approximately 900,000 people in the
United States and is increasing at an alarming rate. Over 75% of these cases are onset at the age of 18 or
younger, hence the antiquated terminology of Juvenile onset diabetes. T1DM develops when an
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individual’s immune system loses the ability to differentiate foreign microorganisms from self [5]; this
results in immune dysregulation and expansion of autoreactive CD4+ and CD8+ T cells, as well as B
lymphocytes and other cells of hematopoietic origin. The disorder is characterized by complete insulin
deficiency secondary to autoimmune-mediated β-cell death, which occurs via a two-step process (Figure
1). The first phase is known as insulitis, in which dendritic cells, macrophages, and lymphocytes (most
abundantly CD8+ T lymphocytes), infiltrate the islet of Langerhans and cause inflammation upon release
of pro-inflammatory cytokines. The islet of Langerhans contains multiple cell types: α, β, δ, ε, and PP
cells, which exhibit endocrine function by their secretion of hormones directly into the bloodstream.
Interestingly, however, T lymphocytes selectively target β-cells for death, leaving all other cell types
residing within the islet free from the cytotoxic effect of these autoreactive cells. The second and final
effector phase of β-cell death is characterized by immune cell-mediated β-cell destruction through
signaling mechanisms that are still unclear [6-8]. Progression of β-cell death is variable in duration, and
clinical symptoms generally begin appearing after the loss of approximately 70-80% of β-cells [9]. Typical

Figure 1. Schematic that diagrams progression of the islet β-cell to autoimmune-mediated death,
and leads to development of overt Type 1 diabetes mellitus.

3

signs of chronic hyperglycemia most commonly include polyphagia, polyuria, polydipsia, weight loss, and
lethargy [10].
After diagnosis of T1DM, treatment involves achieving a critical balance between insulin
administration and food intake; the ultimate goal is to minimize fluctuations in self-monitored blood
glucose levels, that when uncontrolled, enhance the risk for long-term complications. Insulin was
discovered as the secreted pancreatic factor required to cure the disease symptoms [11] and indeed,
insulin administration is still the only therapy available to treat Type 1 diabetes. For a number of years,
subcutaneous injection multiple times daily was the only method of insulin administration. However,
alternative routes of insulin administration have recently become available and provide the capability
for tighter regulation of blood glucose levels, in addition to other factors. For example, the insulin pump
allows for a constant basal insulin drip and is connected subcutaneously, so lessens the invasiveness of
the treatment conferred by insulin injection. Furthermore, the pump may offer a way to maintain
glycosylated hemoglobin (HbA1c) in a narrower range; HbA1c is a good measure of long-term average
blood glucose levels. Importantly, the ability to maintain blood glucose levels near the normal range (70100 mg/dL) significantly lessens the risk for long-term complications [12]. Individuals with poorly
controlled diabetes mellitus are at an enhanced risk for a plethora of long-term complications, including
nephropathy, neuropathy, retinopathy, amputation, heart disease, and earlier than average mortality
rates [13].

II. Predisposing Factors that Affect Risk for T1DM
Some genes have a significant association with T1DM, and can have a role in either protection or
enhanced vulnerability for the disorder. The human leukocyte antigen (HLA) is a region on chromosome
6p21 that is also known as insulin-dependent diabetes mellitus locus (IDDMI). Susceptibility loci found
on the HLA region account for nearly 45% of genetic vulnerability for T1DM, more than any other
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associated gene, although more than 30 non-HLA regions have also been shown to affect risk for the
disease [14]. HLA genes can also be used as markers of risk for T1DM, in combination with the presence
of autoantibodies. This genetic link associated with vulnerability for T1DM is exemplified by family
members of a Type 1 diabetic who themselves are also at enhanced risk for diabetes [15].
External precipitating events are just as noteworthy as genetic background in regards to
triggering an autoimmune response towards the pancreatic islet. However, a more complex model than
one single environmental factor might be required to explain disease onset; indeed, T1DM progresses
through multiple stages, each of which could be influenced by one or multiple environmental triggers
[16]. A number of environmental agents have been associated with enhanced risk for the disease;
moreover, the rising incidence of the disease suggests that there is a corresponding increase in exposure
to such factors. Viral infection is one such factor, and has been heavily investigated for correlation with
T1DM. Indeed, the seasonal peak of enterovirus infections parallels a seasonal rise in incidence of T1DM
[9]. Specifically, antibodies against the Coxsackie B family of enteroviruses have been identified as being
present in recent-onset T1DM patients. However, direct measurement of intra-islet viral presence is
difficult to attain in a non-invasive fashion. Although viral infection is the most well-studied non-genetic
factor associated with vulnerability for T1DM, numerous others have also been suggested to have the
ability to modify disease risk. These include climate, vaccine administration, psychological stress, early
infant diet, exposure to dietary or environmental toxins, sun exposure, and population hygiene [17].

III. Prevention/ Interventions against Overt T1DM
In recent years, a widespread effort has been focused on prevention of T1DM in pre-diabetic
individuals, in addition to disease-abrogating therapies targeted towards overt diabetics. Recent-onset
diabetes patients are the most frequent population that such therapies have been tested on. A number
of interventions that have been successful in animal models of spontaneous diabetes have been further
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investigated in human clinical trials, but none have yet seen permanent remission from disease and such
trials confer a number of limitations. There are currently no biomarkers that correlate with disease
progression, and endpoints for clinical trials are often limited to analysis of β-cell function after a predefined period of time [16]. Furthermore, non-invasive techniques to analyze β-cell mass have not yet
been developed, which prevents direct measurement of therapy effectiveness within the islet. Stem cell
transplantation and islet transplantation are noteworthy potential therapies for T1DM, but outcomes
with these have been overall unsuccessful; the transplanted islets end up susceptible to the same
destructive autoimmune attack as the endogenous islets. Although overt diabetics transplanted with
healthy islets or pancreata have remained insulin-free for a period of time, they often endure a rigorous
regime of immunosuppressant drugs to prevent autoimmune attack on newly-transplanted cells [18].
Prevention trials are of interest in the diabetes community, especially among individuals
identified as high-risk in regards to T1DM development. First-degree relatives of a Type 1 diabetic who
test positive for one autoantibody have a less than 20% risk for disease development, whereas the
presence of two or more circulating autoantibodies confers a 90% risk [16]. However, as in trials for
overtly diabetic individuals, prevention trials have also presented with disappointing results. Participant
recruitment requires screening of a large number of people, since autoantibody frequency among
relatives of Type 1 diabetics is only about 3.5%. Moreover, individuals who do enroll in such trials must
not have already undergone islet autoimmune attack, and experimental conditions must be exact in
regards to dosing of the given experimental agent [16]. Before implementation of a successful
prevention for pre-diabetics or therapy for overt diabetics, a number of barriers need to first be
overcome. Centrally, the autoimmune trigger and mechanism of β-cell death are still unclear; without a
comprehensive understanding of either of these factors, it will be extraordinarily difficult to devise an
effective intervention.
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Elucidation of the β-cell death mechanism has proven challenging to investigators; although it
still remains unclear, a number of proteins and pathways have been suggested to have a role in the
process. Controversy resounds in both the proposed intracellular signaling pathway and whether this
pathway should be classified as an apoptotic or non-apoptotic event [19-21]. Two signaling pathways in
particular have been investigated for a role in β-cell death; Fas receptor and the perforin/granzyme
pathway have critical function in maintenance of immune homeostasis and in mediation of target cell
death. Although research into the role for perforin/granzyme in development of T1DM has been
relatively consistent in that it likely mediates the effector phase of β-cell death, the role for Fas is more
obscure. The signaling pathway initiated by interaction between Fas and Fas ligand (FasL) has been
shown to be both dispensable and indispensable for β-cell death and development of T1DM, although a
number of separate genetic backgrounds, mutations, and transgenic models have been used to derive
these results. This is significant in that each of these model systems might confer separate mechanisms
of β-cell death, and could explain the inconsistencies in Fas β-cell research. This literature review was
undertaken with the intent of reconciling the current state of the Fas β-cell death field. Extensive
searches were conducted to compile all relevant literature (Appendix: Figure 3, Tables 3 & 4), which
was subsequently organized and analyzed based on each group’s choice of model system to test a
similar hypothesis. Each mutation or transgene used in Fas β-cell literature was examined for reported
findings, in addition to strengths and limitations in the context of usefulness for investigation of Fasmediated β-cell death. To date, there is no single document that summarizes the research relevant to
Fas signaling in β-cell death; this document will be innovative in that it will be the first to do so, and will
provide a comprehensive reference for researchers interested in investigating the role for Fas-FasL
interactions in β-cell death and development of T1DM.
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CHAPTER II
Death in the FAS Lane: A Role for Fas Receptor Signaling in Pancreatic
β-Cell Death?
I. Introduction
Type I diabetes mellitus (T1DM) is a chronic autoimmune endocrine disorder that continues to
increase in incidence, and confers an enhanced risk for a number of long-term health consequences.
Although innumerable groups have continued for years to investigate its pathogenesis, the mechanism
of how immune-mediated β-cell death occurs is still unclear. A number of proteins capable of mediating
cell death have been implicated in this process [22], one of which is the Fas receptor (also known as
CD95/APO-1). Interaction between Fas and its respective Fas ligand (FasL/CD95L/APO-1L) has already
been established as critical for homeostasis among cellular populations of the immune system, as well
as in maintenance of immune privilege in some tissues. Because FasL is expressed on the surface of
activated lymphocytes, it is possible that FasL on autoreactive islet-infiltrating cells could mediate
pancreatic β-cell death through interaction with β-cell surface Fas. The ability of Fas to be induced to the
β-cell surface strongly supported this notion [23], and was further investigated with the demonstration
that diabetes-prone mice with a systemic deficiency in Fas or FasL are protected from diabetes
development [24, 25]. However, the absence of Fas-FasL interactions for maintenance of immune
system equilibrium results in a number of physiological abnormalities that affect its natural response to
an autoimmune trigger.
The problems inherent to a systemic Fas deficiency were circumvented by multiple groups that
generated new methods for investigating Fas-FasL interactions in the islet β-cell, without depleting its
function in hematopoietic tissues. However, this resulted in a field comprised of animals and cell lines
from separate genetic backgrounds coupled with knockout mutations and transgenic overexpression, of
which together form an extraordinarily convoluted role for Fas as an effector of β-cell death.
8

If Fas is indeed critical for β-cell death, interruption of the interaction between β-cell Fas and
immune cell FasL should confer a level of protection against β-cell death and ultimately development of
T1DM. This review aims to characterize the role of Fas-FasL interactions in both physiological
homeostasis and in β-cell pathology leading to T1DM, and will investigate the proposed links between
its known homeostatic functions and its potential ability to mediate autoimmune pathogenesis leading
to T1DM. Additionally, we will identify and relate the studies of Fas/FasL on β-cell death by presenting
their findings, inconsistencies in relation to each other, and alternative approaches for therapeutic use
of Fas-FasL in protection of the β-cell from autoimmune-mediated death. From these findings, future
investigators interested in the role for Fas and FasL in β-cell death will be better equipped to choose an
appropriate model system for derivation of findings that could ultimately translate to therapeutic
interventions.

II. Characterization of Fas & FasL
General Mechanism of Action
Discovery of the Fas receptor was preceded by the synthesis of two monoclonal antibodies that
recognized the same target receptor; both had cytolytic activity in a variety of human cell types, and
were termed anti-APO-1 (apoptosis antigen 1) and anti-Fas [26, 27]. Isolation of cDNAs encoding the
antigen to anti-Fas led to identification and characterization of the Fas receptor [28], whose gene lies on
human chromosome 10q24.1 [29], and on its homologous mouse counterpart chromosome 19 [30].
Characterization of the APO-1 antigen and its nucleotide sequence revealed that it lay on chromosome
10q23 [31] and shares sequence identity with Fas antigen gene [26]; hence, the terms Fas and APO-1 are
often used interchangeably.
The Fas protein is a trimeric receptor that is a member of the death receptor (DR) subfamily and
is part of the larger tumor necrosis factor receptor (TNF-R) superfamily [32]. Members of the DR
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subfamily share a cysteine-rich extracellular domain and a cytoplasmic region, which is referred to as a
death domain (DD), and is required for apoptotic signal transduction upon receptor activation [33, 34].
Additionally, the receptor is characterized as a type I transmembrane protein due to the location of its
extracellular N-terminal and intracellular C-terminus [28]. The cytolytic activity initiated by binding of
anti-Fas to its receptor suggested that Fas might have a natural ligand which communicates an apoptotic
signal. Indeed, the Fas ligand (FasL/CD95L/APO-1L) was first identified on the surface of a cytotoxic T cell
hybridoma by use of soluble Fas antigen [35], and soon after confirmed to be the ligand specific for Fas
receptor; activation of the receptor induced cytotoxic activity against Fas-expressing cytotoxic T
lymphocyte (CTL) hybridomas but not against those lacking Fas activity [36].
FasL is a member of the TNF family whose gene resides on human and mouse chromosome 1
[37, 38], and is classified a type II transmembrane protein due to the presence of an internal
hydrophobic domain and a COOH-terminal region that resides outside the cell [8]. Although it occurs
naturally in a membrane-bound form (mFasL), mFasL cleaved by metalloproteinases results in a soluble
form of the ligand (sFasL), which can exist as a trimer [39, 40]. Whereas sFasL can still bind Fas, mFasL is
a much more potent stimulus for cytotoxic activity than sFasL. [41-43]. In fact, sFasL has been shown to
promote autoimmunity, tumorigenesis, and protection from the apoptotic effects of mFasL [44, 45],
although it can still function as a death effector [40].
Fas-FasL interactions occur in an autocrine or paracrine fashion through one of three types of
interactions [8]:
1. trans interaction; Fas and mFasL, expressed on the surface of distinct cells, cross-link to
mediate death of the Fas-expressing cell.
2. cis interaction; both Fas receptor and mFasL are expressed on the surface of the same target
cell.
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3. sFasL binds to Fas expressed on the same cell sFasL is released from (cis), or sFasL binds to Fas
on the surface of a neighboring cell (trans).
Binding of FasL to its receptor induces trimerization of Fas and initiates a conformational change
within the cytoplasmic death domain that promotes association of an intracellular Fas-associated death
domain (FADD), pro-caspase-8, and the caspase-8 regulator cellular FLICE-like inhibitory protein (cFLIP);
these together comprises the death-inducing signaling complex (DISC). Although cFLIP is most
commonly an anti-apoptotic molecule, the cFLIP long (cFLIPL) isoform can support cell death [46]. The
FADD promotes oligomerization of procaspase-8 and through autoproteolysis is subsequently released
as active caspase-8 into the cytoplasm [46]. At this stage of the apoptotic pathway, the type of cell in
question determines how the pathway will proceed; this can be either directly through an extrinsic
pathway (type I cell) or indirectly through an intrinsic mitochondrial pathway (type II cell) [47](Figure 2).
Cell types such as thymocytes, activated T cells, and B lymphoma cells characterize the type I cell

Figure 2. Schematic representation of the Fas-induced signaling pathway that leads to AICD and target
cell death.
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[48], whereas hepatocytes and β-cells are classified as type II cells [49, 50]. X-linked inhibitor of
apoptosis (XIAP) is the only member of the mammalian IAP protein family that directly inhibits caspases
and acts on the effector caspases -3 and -7 [51]. This mechanism discriminates between type I and type
II apoptosis, because the absence of XIAP causes hepatocytes to undergo apoptotic death independent
of the mitochondrial pathway [52, 53]. In contrast with type I cells, type II cells have much lower levels
of Fas-dependent DISC formation and subsequent caspase-8 activation [46]. The limited availability of
active caspase-8 in type II cells prevents accumulation of adequate quantities of cleaved caspase-3 for
facilitation of apoptosis; such quantities of caspase-8 are, however, sufficient to cleave Bid and allow
type II cells to progress through the intrinsic mitochondrial pathway [54, 55].
Downstream of caspase-8 activation, type II cells proceed through a mitochondrial pathway
initiated with caspase-8-mediated cleavage of the BH3-only protein Bid. Newly-cleaved tBid, facilitated
by interaction with mitochondrial carrier homologue 2/Met-induced mitochondrial protein
(MTCH2/MIMP), translocates to the mitochondrial outer membrane to activate the pro-apoptotic
proteins Bax/Bak [56]. Bax/Bak mediate mitochondrial outer membrane permeabilization (MOMP),
releasing a second mitochondria-derived activator of caspase/direct IAP binding protein with low pl
(Smac/DIABLO) [57], cytochrome c, and other apoptogenic factors from the mitochondria. In the
presence of ATP, cytochrome c binds apoptotic protease activating factor-1 (APAF-1) to form the
apoptosome; recruitment of inactive caspase-9 to the apoptosome leads to its autoactivation, allowing
it to cleave caspase-3 [58]. Additionally, the XIAP antagonist Smac/DIABLO promotes caspase-3 cleavage
by blocking XIAP-caspase-3 binding [51, 53](Figure 2).
By contrast, type I cells use caspase-8 to directly cleave and activate caspase-3 [53]. Active
caspase-3 induces proteolysis of structural proteins and other essential cellular components, leading to
the hallmark characteristics of apoptosis. Although Fas-FasL interactions are most well-characterized for
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their apoptotic activities, survival pathways may also be initiated; however, these concepts are beyond
the scope of this article (see Ref. [59-62] for further review).

Constitutive Expression
The Fas receptor is constitutively expressed in a variety of tissues throughout the body, with
abundant expression in the thymus, liver, ovary, and heart [30]. Fas mRNA expression has also been
demonstrated in thymocytes, where activation of mature T and B cells promotes Fas cell surface
induction [63, 64].
Because of its ability to induce death in Fas-expressing cells, FasL tissue expression is tightly
controlled. FasL mRNA is constitutively expressed in a select range of tissues, centrally splenocytes and
thymocytes, and its cell surface expression can be induced after activation of T lymphocytes and natural
killer (NK) cells [35, 39]. FasL mRNA has also been demonstrated at low levels in mouse lungs, small
intestine, kidney, and liver [65, 66], and the protein is constitutively expressed on the cell surface of
immune-privileged tissues such as the eye, testes, and thymus [66, 67].
FasL assists in maintaining immune privilege in a number of tissues, where its constitutive
expression at the surface of such sites can induce apoptosis in activated Fas+ infiltrating lymphocytes
[66-68]. Immune privilege is generally defined as a situation in which a tissue is protected from immune
infiltration, even during foreign invasion, as the proinflammatory immune response would be more
destructive than its foreign target [69]. The eye is the most well-characterized site of immune privilege
and multiple studies support a role for FasL in prevention of immune infiltration in the eye [66, 67].
Additionally, the cornea has an 80-90% transplantation success rate with no immunosuppressant use
[69], and FasL expression is required for corneal graft survival [70]. Studies in the testes have shown
similar results; loss of FasL expression in testicular grafts transplanted under mouse kidney capsule
causes them to undergo immune infiltration and rejection, yet transplants that express FasL can survive
[68].
13

The concept of immune privilege has also been extended to tumor cells that express FasL and
are therefore resistant to lymphocyte invasion, supporting a role for FasL in tumorigenesis [71, 72].
Inhibition of FasL expression in murine colon tumor cells suppresses tumor growth and formation and
increases lymphocyte infiltration [73], indicating that tumor FasL expression encompasses both
defensive and offensive strategies for tumor survival. However, controversy surrounds the role of FasL in
tumor immune escape, likely stemming from transplantation studies in which FasL overexpression can
cause rejection of tissue transplants [72]; although beyond the scope of this article, the interested
reader is directed to Ref. [74] for further review.

Role in Immune Homeostasis
Immune homeostasis is known as the capability of an organism to maintain equilibrium among
cells of hematopoietic origin. One of the important roles for Fas-FasL interactions is in maintenance of
immune homeostasis by preventing overgrowth in this cellular population, and is particularly significant
for CD4+ and CD8+ T lymphocytes [75-77]. CD4+ T cells are referred to as helper T (TH) cells and shape
adaptive immune responses by producing cytokines and enhancing expression of costimulatory factors.
CD8+ T cells, in contrast, are known as cytotoxic T (TC) cells due to their direct role as cytotoxic effectors
against target cells, but are also capable of cytokine production [78].
To mount an appropriate T cell-mediated response, the immune system first requires a method
of antigen recognition. This is accomplished by a high-affinity interaction between the T-cell receptor
(TCR)/CD3 complex with MHC-associated antigenic peptide [79]. Appropriately regulated lymphocyte
growth and maintenance are critical for prevention of recognition of self antigens and initiation of
autoimmunity.
Differentiation from a multipotent hematopoietic stem cell to mature T cell is a complex process
that requires a coordinated effort by various transcription factors and regulatory mechanisms. Although
they originate in the bone marrow, T cell precursors migrate to the thymus to undergo maturation as
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thymocytes and can eventually become self-restricted single positive (SP) CD8+ or CD4+ T lymphocytes
[80].
On arrival to the thymus, T cell precursors do not express any of the characteristic cell surface
markers of a mature T cell; additionally, approximately 95% of mouse thymocytes express the Fas
protein on their cell surface [81]. A period of rapid proliferation continues through the first two of four
double negative (DN) stages of development (CD4- CD8-), all of which are characterized by the
coordinated expression of specific cell surface markers [82]. DN2 thymocytes begin the rearrangement
of a T cell receptor TCR-β chain and conclude the process of somatic recombination upon progression to
the DN3 stage [79, 83].
Progression to the DN3 stage indicates commitment to the T cell lineage [80], and the DN4 stage
is a period of rapid proliferation preceding transition to double positive (DP) thymocyte which confers
cell surface expression of both the CD4 and CD8 coreceptors [84]. TCR-α chain rearrangement, occurring
at the conclusion of this final proliferative stage, marks TCR completion and movement to the rigorous
process of thymic selection, from which only 5% of the original thymic population emerge as mature T
cells [84]. Thymic selection comprises three checkpoints that must all be cleared for a thymocyte to
become a mature T cell: death by neglect, positive selection, and negative selection.
Death by neglect occurs alongside positive selection, and is a passive form of cell death
in which a cortical thymocyte fails to receive necessary signals for survival, as its TCR has not ligated with
MHC-self peptide. The vast majority of cortical thymocytes, approximately 90%, die during positive
selection, specifically by failing to receive survival signals that are transmitted upon cross-linking of TCR
with MHC-self peptide [84].
Characterized by MHC restriction, positive selection ensures that the mature T cell can recognize
self-MHC complexes, a necessary quality for eliciting an immune response against a foreign antigen. TCR
expression enables low-affinity binding with MHC Class-I or Class-II bound with self peptide, which must
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be recognized by the DP thymocyte. Thymocyte TCR cross-linking with MHC-self antigen promotes
thymocyte survival and movement to the next stage of thymic selection [82].
In contrast to positive selection, negative selection only clears approximately 5% of the initial
thymocyte pool [84] but is fundamental to prevention of an autoimmune response. Negative selection is
characterized by high-affinity engagement of the thymocyte TCR with self-MHC from dendritic cells (DC)
or medullary epithelial cells, resulting in apoptotic death; only moderate-affinity interactions between
TCR and MHC-self peptide allow for survival during the negative selection process.
Although not critical for thymic negative selection [85-87], Fas-FasL interactions are
indispensable for peripheral selection, or post-maturation hematopoietic cell deletion, and maintenance
of immune homeostasis. This was illustrated by loss-of-function mutations in both Fas receptor and Fas
ligand. Lymphoproliferation (lpr) is an autosomal recessive mutation in the Fas receptor that was first
identified in MRL/MpJ mice and has since been localized to mouse chromosome 19 [88, 89]. Generalized
lymphoproliferative disorder (gld) is a mutation in FasL that originated in the C3H/HeJ mouse strain [90]
on mouse chromosome 1 [38], and although nonallelic to lpr, produces nearly identical serological and
immunopathological markers as lpr on the same mouse strain. These mutations were originally
postulated to be involved in metabolic cycling until bone marrow transfer experiments conducted by
Allen et al. suggested that they might be mutations in a pair of interacting molecules, such as that of
receptor and ligand [91]. Indeed, genetic mapping analysis showed that lpr is located in close
chromosomal proximity to the Fas receptor [92], and gld to that of the Fas ligand [38]. lpr is thus a
mutation in Fas receptor and gld a mutation in Fas ligand, discoveries made through comparison of wildtype (wt) and mutant cells for Fas and FasL gene expression [38, 92].
The lpr mutation occurs as a result of premature splicing due to insertion of a early transposable
element (ETn) containing two poly-A adenylation sites at the long terminal repeat (LTR) region within
intron 2 of the Fas antigen gene [93]. Although initiated normally, Fas mRNA transcription is terminated
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before exon 3, resulting in limited expression and function of the Fas receptor in both MRL/MpJ and
CH3/HeJ mice [92]. However, lpr is a leaky mutation; Fas receptor can be expressed in lpr/lpr mice, at
approximately 1-2% of the wild-type level [94]. FasL is constitutively expressed and fully functional in
lpr/lpr mice [95]. lprᶜᵍ, a dominant-negative mutation that is allelic to lpr, was originally detected in
mutant mice from the CBA/K1 mouse strain [96] and is known as ‘lpr complementing gld’ due to its
ability to induce weaker lymphadenopathy than lpr/lpr when the heterozygous gld/+ mutation is also
present [97]. lprᶜᵍ also blocks functional Fas expression, but through a point mutation in the cytoplasmic
apoptotic signal-transducing region of the Fas gene. Although lprᶜᵍ Fas is expressed at similar levels as
wild-type, the receptor cannot transmit a death signal and is thus nonfunctional [81, 92].
gld, the loss-of-function mutation in FasL, is characterized by a point mutation within the
extracellular region of the FasL [38]. Unlike lpr, which limits Fas expression, gld still confers FasL
expression. And although it has a low level of function, FasL in gld/gld mice displays the same
constitutive expression pattern as in lpr/lpr mice [95, 98].
The physiological and etiological implications of homozygosity for lpr/lpr and gld/gld are nearly
the same. Both mutations incur massive lymphoproliferation and progressive infiltration of the spleen
and lymph nodes with nonmalignant double negative (DN) CD4-, CD8-, and Thy1+ T cells, as well as
increased cell surface expression of B220, which is normally expressed on B cells, and other abnormal T
cell-surface markers [99], all of which manifest in an age-dependent manner [99]. Enhanced production
of autoantibodies such as anti-ssDNA, IgG, and IgM [100] in lpr/lpr and gld/gld mice, links these murine
mutations to their closest human syndrome, an autoimmune disease known as systemic lupus
erythematosus (SLE) [101]. Another such disorder, autoimmune lymphoproliferative syndrome (ALPS),
often confers a mutation in the Fas gene and results in symptoms similar to that seen in lpr/lpr mice
[102]. Finally, the lpr gene is fittingly expressed in bone marrow hematopoietic stem cells [99], the site
of origin for the global immune T cell population [8].
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The immunological implications of lpr/lpr and gld/gld, coupled with the demonstration of Fas
receptor expression on the cell surface of activated B and T cells [64, 103], led to the postulation that
Fas-FasL interactions play a critical role in immune homeostasis [87, 92, 104]. Studies conducted with
both lpr/lpr and Fas¯/¯ mice indicate an obligatory role for Fas in peripheral clonal deletion, as
evidenced by lymphocyte accumulation in the spleen and lymph nodes of the mutated mice [86, 87,
105]. Additionally, when the Fas transgene is expressed in lpr/lpr mice the lymphoproliferation
phenotype is abolished, reinforcing the indispensable role of Fas-FasL interactions in peripheral deletion
[106].
Another critical role for Fas-FasL interaction in the immune system is the ability to mediate
target cell death by signaling from CTLs and NK cells; this is in combination with other mechanisms,
namely the perforin/granzyme pathway, in which exocytosis of perforin granules and granzyme B from
the CTL causes target cell death [8, 22, 107, 108]. Although their method of target cell recognition are
different, CTLs and NK cells kill by the same lytic mechanism [109]. Naïve lymphocytes store FasL in
intracellular lytic granules [110], and TCR/CD3 lymphocyte stimulation causes FasL localization to the
immunological synapse [111]. This event is controlled by a proline-rich domain in the cytoplasmic tail of
FasL, and is critical for prevention of constitutive FasL on the surface of activated cytotoxic cells. Ligation
of cell surface FasL to target cell Fas then initiates the signaling cascade as described above (Figure 2).
Conclusion of this cytotoxic activity and the expansion phase mark the start of a contraction phase,
whereby immune cells begin undergoing activation-induced cell death (AICD) to bring the cell numbers
down to normal levels [112] and prevent overgrowth that is seen in homozygous lpr/lpr and gld/gld
mice.
Antigen-presenting cells (APC) are another type of immune cell, which present antigen on their
cell-surface MHC complex for interaction with TH and TC cells and have the ability to secrete cytokines;
professional APCs, which express an MHC class II complex, are characterized by B lymphocytes, DCs, and
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macrophages. B lymphocytes are most easily distinguished from T lymphocytes by the presence of the
CD40 B cell receptor (BCR), a membrane-bound immunoglobulin that is heavily involved in activation
and determination of cell fate [113]. In addition to their function as APCs, B cells can produce antibodies
to enable cytotoxic activity. Fas expression has been detected on B cells, albeit to a lesser extent than T
cells [64], with a marked increase in cell surface expression upon activation and corresponding increase
in sensitivity to Fas-mediated lysis [114]. Fas-mediated B cell elimination is critical for homeostasis,
where its absence leads to autoimmune manifestations such as hyperimmunoglobulinemia and
splenomegaly [115]. In conclusion, these data indicate an essential role for Fas-FasL interactions in APC
elimination and B cell-mediated target cell death; however, Fas-FasL probably acts in concert with other
known death effectors.

III. Role of Fas Signaling in β-Cell Death
Failure to appropriately regulate the immune system’s autoreactive T cell repertoire can
promote autoimmune disease. A classic example of this occurs in type 1 diabetes mellitus (T1DM), a
common endocrine disease that is characterized by selective immune-mediated destruction of insulinsecreting pancreatic β-cells [116]. T1DM development is initiated with insulitis, a term describing
immune cell accumulation in both the periphery as well as within the islet of Langerhans. This immune
cell invasion is followed by an effector phase whereby leukocytes recognize exposed β-cell antigens
presented by MHC complexes on the surface of APCs within the islet and instigate β-cell death [117].
Both CD4+ and CD8+ CTLs are critical for autoimmune-mediated β-cell death [118, 119]. In support of
this, immunohistological analysis has shown leukocytic islet infiltrates to be mostly composed of T cells
[116]; CD4+ lymphocytes are the central effector in this process [120, 121]. DCs and macrophages, also
present in the islet infiltrate, are the first invaders that trigger the adaptive immune response, typically
through release of the pro-inflammatory cytokine interleukin-1β (IL-1β) [122-124]. Invading T
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lymphocytes and resident macrophages secrete IL-1β and by virtue of signaling through the IL-1
receptor (IL-1R) on the islet β-cell surface, produce key intracellular events in the development of
insulitis and β-cell death. Moreover, when primary islets or insulinoma cell lines are exposed to IL-1β
alone or IL-1β combined with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), there
is a loss of cellular function as measured through GSIS and eventual progression to cell death [19-21,
123, 125, 126]. Finally, IL-1β-stimulated increases in the inducible form of nitric oxide synthase (iNOS),
which catalyzes production of nitric oxide (NO), likely acts as a direct mediator of β-cell death [21, 127129]. However, the molecular mechanism underlying cytokine-mediated β-cell destruction is still not
well understood. Although MHC class II expression on autoreactive CD4+ lymphocytes is normally
required for autoantigen recognition, its expression has not been observed on islet-invading CD4+
lymphocytes [130]. Additionally, it is unlikely that there is one single effector mechanism of β-cell death,
and likely varies amongst species and even individuals. Multiple proteins capable of instigating cytotoxic
intracellular signaling might have a role in the process, with evidence implicating perforin/granzyme,
TNF/TNFR1, and Fas-FasL [6, 7, 22, 24, 131-133].
The majority of studies investigating the mechanism of β-cell death and development of T1DM
have focused on a potential role for Fas-FasL interactions. Although Fas and FasL do not contribute to
genetic susceptibility for T1DM [134-136], their interaction was initially implicated in β-cell death when
autoimmune diabetes-prone non-obese diabetic (NOD) mice carrying the lpr/lpr mutation failed to
develop diabetes [24, 25]. Adoptive transfer of diabetogenic CD8+ islet-specific T cells or total
splenocytes also failed to induce diabetes in Fas-deficient lpr/lpr mice [24, 25]. Moreover, IL-1β-induced
β-cell-surface Fas expression could provide a mode of β-cell death by Fas receptor activation [23]. These
findings led to the commencement of a span of studies that explored the role for Fas-FasL interactions in
β-cell death, yet the complexities involved with islet physiology have made it difficult to conduct in vivo
Fas β-cell studies. Accordingly, multiple systems have been designed to simulate a human diabetes
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patient (Tables 1 & 2), and have majorly contributed to the inconclusive and conflicting results of
subsequent Fas β-cell death studies. This review summarizes the progression of the Fas β-cell field by
reporting the ex vivo genetic manipulations and transgenic models, and whether or not these confirm a
dependence on Fas-FasL interactions for β-cell death and development of T1DM.
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Table 1. Summary of mutations and transgenes that comprise
spontaneous and pharmacologically-induced models used for
investigation of Fas-mediated β-cell death.
*Mice of non-NOD genetic background
Method of diabetes
induction

Mutation/Transgene

Reference

lpr/lpr

[24, 25, 137]

gld/gld

[138]

Spontaneous

RIP-lpr

cg

[139]

lpr/+

[24, 138, 140]

gld/+

[139, 141]

IL-10R-neutralized-gld/+

[142]

IL-10-transgenic-lpr/lpr

[143]

IL-1β¯/¯, ICE¯/¯

[144]

4.1-NOD.lpr/lpr

[145]

Ad-IL-1R¯/¯

[146]

4.1-NOD/RIP.SOCS-1

[147]

RIP-dnFADD

[148]

BID¯/¯

[149]

+

fl/fl

RIP-Cre Fas

Cyclophosphamide

Neutralizing anti-Fas Ab
at 2-4 weeks old

[151]

FasL-neutralizing Ab

[152]

+

MLDS

CD8+ T cell-mediated

[150]

+/-

fl/fl

TCR-HA Ins-HA Fas ,
+/RIP-Cre *

[153]

BDC2.5/NOD-lpr/lpr

[154]

RIP-Cre Fas *

+

[155]

AdCTLA4-FasL*

[156]

RIP-SOCS-1.NOD8.3

[157]
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fl/fl

Table 2. Summary of adoptive transfer models from in vivo studies that investigated the role of Fas-FasL interactions
in β-cell death.
*Treated with a neutralizing/antagonist anti-FasL antibody
**Pharmacologically induced to diabetes
Cell Type

Splenocytes

Genetic
Background

Donor

Recipient

Reference

Donor

Recipient

Reference

NOD-wt

NOD-lpr/lpr

[24, 139,
140]

NOD-wt

diabetic NOD-wt

[137]

NOD-wt

NOD-scid/scid

[141]

NOD-wt

diabetic NOD-wt*

[158]

NOD-wt

NOD-scid/scidgld/gld

[141]

NOD-wt

male NOD-wt**

[137]

diabetic NOD-wt

NOD-wt*

[151, 152]

C3H/HeJ-wt

NOD-wt**

[159]

diabetic NOD-wt

NOD-scid/scidlpr/lpr

[138, 139]

NOD-lpr/lpr

NOD-wt

[152]

NOD-wt

[160]

NOD-lpr/lpr

male NOD-wt**

[137]

IL-10-transgenic NOD-lpr/lpr

NOD-scid/scid

[143]

NOD-lpr/lpr

diabetic NOD-wt

[137]

NOD-lpr/lpr

NOD-scid/scid

[143]

C3H/HeJ-lpr/lpr

NOD-wt

[159]

NOD-gld/+

NOD-scid/scid

[141]

SA-FasL from diabetic NOD

Cell Type
Genetic
Background

Pancreatic Islets

CD8+ islet-specific T cells
Donor

Recipient

CD4+ islet-specific T cells
Reference

Donor

Recipient

Reference

NOD-wt

NOD-lpr/lpr

[25]

NOD-wt

NOD-wt

[151]

NOD-wt

NOD-wt*

[151]

YNK7.3 clones, no
donor

NOD-lpr/lpr

[151]

HA-specific from Balb/c
clone-4 TCR transgenic

Balb/c Ins-HAlpr/lpr

[161]

HA-specific from TCRHA transgenic RAG-2¯/¯

INS-HA-RAG-2¯/¯

[153]

OVA-specific from OT-1 TCR
transgenic

B6.MRL-lpr/lpr

[162]

HA-specific from TCRHA transgenic RAG-2¯/¯

INS-HA-RAG-2¯/¯Fas¯/¯

[153]

NOD-8.3

[163]

NOD-8.3 from NOD-lpr/lpr

23

lpr & gld, Loss-of-Function Mutations
Although the original lpr/lpr mouse was identified in the MRL/MpJ mouse strain, the mutation is
often transferred to the non-obese diabetic (NOD) mouse for β-cell studies investigating the
contribution of the Fas receptor. The NOD mouse is the most frequently used murine model for diabetes
studies because it develops the disease in a T cell-dependent manner that is reminiscent of a human
T1DM patient [164, 165]. There is a difference in rate of diabetes onset between male and female NOD
mice. Females have decreased insulin content at 12 weeks of age and a 90-100% diabetes incidence by
30 weeks old; males have a 40-60% incidence by the same age. Female NOD mice are thus more
appropriate for spontaneous diabetes studies, whereas males are well-suited for studies of accelerated
disease transfer (Jackson Labs website). Fas expression is elevated in female NOD mice at 15 weeks of
age relative to their male counterparts and correlates with the overall gender difference observed in
NOD mice [166]. Similar to the MRL-lpr/lpr model, NOD-lpr/lpr mice develop lymphadenopathy and
massive infiltration of nonmalignant DN CD4- and CD8- T cells [24, 138].
The initial studies implicating Fas-FasL interactions in β-cell death showed that NOD-lpr/lpr mice
failed to develop spontaneous diabetes as compared with their wild-type littermates [24, 25]. FasLdeficient NOD-gld/gld mice were also protected from diabetes development [138]. Further, adoptive
transfer of CD8+ islet-specific T cells or diabetogenic splenocytes from NOD-wt donor mice to NODlpr/lpr mice failed to initiate diabetes, and together these studies indicated a significant role for Fas-FasL
interactions in development of autoimmune diabetes [24, 25]. The lprᶜᵍ mutation is less commonly used
in Fas β-cell studies, but one group showed some protection from development of spontaneous
diabetes amongst NOD mice carrying the lprᶜᵍ mutation, which was driven by the rat insulin promoter
(RIP) and thus confers β-cell-specific expression; the extent of diabetes protection was dependent on
the level of transgene expression [139]. This is a significantly different observation from the lpr/lpr and
gld/gld studies because the systemic Fas deficiency could confer altered immune function that results in
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prevention of autoimmune-mediated β-cell destruction, as opposed to diabetes prevention by loss of
Fas specifically in the β-cell.
The validity of the lpr/lpr mouse as a reliable model for Fas β-cell studies has been subsequently
questioned [137, 140]. The systemic Fas deficiency introduced by a homozygous lpr/lpr mutation may
prevent diabetes, not due to absence of Fas from β-cells, but as a consequence of an inappropriately
functioning immune system that cannot generate a normal inflammatory response [137, 138, 140, 152];
abnormal CD4- CD8- B220+ cells of NOD-lpr/lpr mice are also more resistant to sublethal irradiation
relative to their NOD-wt counterparts [167]. Additionally, failure of adoptively transferred splenocytes
to initiate diabetes in recipient NOD-lpr/lpr mice occurs as a result of constitutive FasL expression on
endogenous lymphocytes, which arises as one of multiple abnormalities resulting from the lpr/lpr
mutation. FasL overexpression on NOD-lpr/lpr lymphocytes kills diabetogenic Fas-expressing cells
through cell surface Fas-FasL interactions before diabetes can be transferred to the recipient mouse
[137, 140]. Furthermore, localization of the gld/gld mutation to hematopoietic tissues by adoptive
transfer of gld/gld bone chimeras into NOD-wt mice results in DN lymphoproliferation, demonstrating
that FasL deficiency on immune cells is the cause of the abnormal phenotype that occurs in gld/gld mice
[141]. In order to circumvent the confounding immunological effects of the NOD-lpr/lpr and NODgld/gld mouse, alternative genetic alterations and methods of diabetes induction such as islet
transplantation and heterozygosity for lpr and gld have been developed and will be described below.
Interestingly, the abnormal phenotype associated with homozygosity for lpr and gld is not
evident in mice that are heterozygous for either mutation. Heterozygotes behave in a comparable
fashion to wild-type mice; whereas NOD-lpr/lpr mice fail to develop diabetes, NOD-lpr/+ develop
diabetes at a similar rate to wild-type mice [24, 140]. Further, although NOD-gld/+ mice have a 0%
incidence of spontaneous diabetes, they have normal-sized lymphoid organs and don’t develop
lymphadenopathy or splenomegaly [138]. The absence of lymphoproliferative effects in gld/+ mice
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indicates that these mice have a sufficient decrease in FasL expression to prevent β-cell death, but there
is adequate FasL expression to prevent the immune implications that result from a complete loss of FasL
[141].
IL-10 is an anti-inflammatory cytokine that has a significant role in growth and differentiation of
various hematopoietic cells and can prevent onset of some inflammatory conditions [168]. Although its
involvement in T1DM development is ambiguous, IL-10 might be protective against diabetes
development in NOD-gld/+ mice. Neutralization of pancreatic B cell-surface IL-10 receptor (IL-10R)
causes a mostly CD4+ T cell-comprised islet cell infiltration, but not transition to diabetes [142].
However, this protective effect is likely specific to NOD-gld/+ mice that do not naturally develop
diabetes, as blocking of the IL-10R in NOD-wt mice has little consequence on insulitis or diabetes
incidence. Additionally, β-cell-specific gene transfer using recombinant adeno-associated virus vector
(AAV) for IL-10 in NOD-wt mice has little protective effect against diabetes development [169]. These
recent findings corroborate the above results in NOD-wt mice yet dispute the IL-10-mediated diabetes
protection observed in NOD-gld/+ mice. Moreover, another group actually reported an acceleration of
NOD diabetes when made transgenic for IL-10. They showed that this acceleration was independent of
Fas, in that NOD-lpr/lpr mice were not protected from IL-10-induced diabetes. Splenocytes from these
mice were able to transfer diabetes to NOD mice deficient in T- and B-lymphocytes by the severe
combined immunodeficiency (scid) mutation (NOD-scid/scid), in contrast to their non-IL-10-transgenic
NOD-lpr/lpr counterparts that could not cause this induction [143]. Yet lymphocytes from NOD-gld/+
mice still carry diabetogenic potential, as NOD-scid/scid mice reconstituted with splenocytes from NODgld/+ or NOD-wt mice develop diabetes at similar rates to each other [141].
A novel approach of analyzing the NOD-gld/gld mouse was taken by separating FasL expression
in the hematopoietic and nonhematopoietic compartments of NOD-gld/gld mice and showed that
blocking Fas expression in either compartment could prevent diabetes incidence [141]. However,
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experiments in which wild-type splenocytes failed to cause diabetes in NOD-scid/scid-gld/gld mice with
a systemic deficiency in FasL and the T- and B-lymphocyte population (but are Fas-sufficient)
demonstrated that protection from diabetes development in NOD-gld/gld and NOD-gld/+ is not a result
of abolished β-cell Fas-FasL signaling and thus favors a Fas-independent mechanism of β-cell death
[141].
Sublethally irradiated NOD-lpr/lpr mice did not develop spontaneous diabetes upon adoptive
transfer of diabetogenic cells [24, 25, 137] because abundant FasL in NOD mice homozygous for the lpr
mutation was likely killing the adoptively transferred splenocytes [137, 140]. Therefore, the destructive
role of Fas-FasL interactions in murine autoimmune β-cell death was investigated by grafting islets from
murine lpr/lpr or wild-type mice into non-diabetic NOD-wt mice. Adoptive transfer of pancreatic islets
from lpr/lpr donor mice into wild-type recipients should confer some level of islet survival if Fas were to
play a necessary role in β-cell death, in that absence of functional Fas on the donor islet would prevent
initiation of the intracellular death cascade via interaction with endogenous recipient FasL. However,
after adoptive transfer of diabetogenic splenocytes to male NOD mice that had been grafted prior with
fetal pancreatic islets from NOD-lpr/lpr or NOD-wt mice, the NOD-lpr/lpr β-cells fared better than the
NOD-wt islets although both were eventually destroyed [137]. While modest, these findings suggest a
role for Fas in autoimmune β-cell destruction. Another group also reported effective destruction of
lpr/lpr islets transplanted into NOD-wt mice, and concluded a dispensable role for Fas-FasL in β-cell
death but did not transplant wild-type islets for comparison [152]. Injection of a neutralizing anti-FasL
antibody (Ab) did not affect diabetes incidence after adoptive transfer of diabetogenic splenocytes or
diabetes induction with cyclophosphamide (CY), indicating Fas-independent β-cell death. In contrast,
treatment with a neutralizing anti-FasL Ab after syngeneic islet transplantation to diabetic NOD mice
restored normoglycemia [158]. Additionally, CH3/HeJ-lpr/lpr islets survived as indicated by normal blood
glucose for up to 2 months in their wild-type recipient after diabetes induction with streptozotocin
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treatment. Although the wild-type islets were destroyed, there was evidence of CD4+ and CD8+
lymphocyte migration to the kidney capsule in both models, which indicates Fas-independent insulitis
but an effector phase of β-cell death that may be Fas-dependent [159]. Furthermore, NOD-lpr/lpr fetal
pancreas grafts could not reverse diabetes in diabetic female NOD mice; although the NODlpr/lpr islets fared better relative to wild-type islets, they were eventually destroyed [137].
Another way to reduce peripheral lymphoid populations and constitutively-expressed FasL
conferred by the lpr/lpr mutation is to delete the potentially abnormal T and B cells altogether. This
model requires use of the scid mutation [170]; studies investigating diabetes incidence in scid/scidlpr/lpr mice used mouse models of similar genetic background and diabetes induction, and were
consistent in their reported results. Reconstitution of sublethally irradiated NOD-scid/scid-lpr/lpr mice
with diabetogenic spleen cells conferred a significant reduction in diabetes incidence relative to NODscid/scid mice that carry functional Fas [138, 139]. This could infer both Fas-dependent and –
independent mechanisms; the primary justification is that the reduction in diabetes incidence could now
be directly attributed to absence of Fas expression. An alternative explanation is that the lpr/lpr
mutation allows for a sufficient level of functional Fas receptor activity or that autoimmune disease in
the adoptive transfer model can also be initiated by Fas-independent mechanisms. This would
potentially allow for a low level of diabetes incidence.
Studies using the lpr and gld mutations, either alone or paired with other mutations, genetic
models, or methods of diabetes induction, comprise the majority of the Fas β-cell field (Tables 1 & 2).
Although the homozygous mutations alone confer a dysfunctional immune system and abnormal
phenotype that make it difficult to directly address the role of Fas-FasL interactions in β-cell death, a
number of groups have found ways to circumvent these abnormalities and manipulate the mutations in
combination with other genetic modifications to investigate the mechanism responsible for
autoimmune-mediated β-cell death.
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Induction of β-Cell Surface Fas Expression
Although the lpr/lpr mutation sparked initial interest in Fas-dependent β-cell death, support for
Fas involvement was built on the ex vivo demonstration that isolated islets from both diabetic rodents
and humans have abundant Fas β-cell surface expression [25, 131, 171-173], whereas β-cells isolated
from disease-free organisms have negligible quantities of cell-surface Fas expression [174-176]. To
corroborate these findings, syngeneic islets from non-diabetic donors transplanted into diabetic NOD
mice had abundant levels of Fas expression, whereas their normoglycemic counterparts had a
significantly lower level of Fas expression [177]. In addition, adoptive transfer of spleen cells from
diabetic NOD donor mice conferred Fas expression in β-cells of recipient NOD-scid/scid mice [178].
Some murine studies, however, reported low levels of Fas expression on the β-cell surface of diabetic
NOD and mice induced to diabetes with CY [179-181], which may reflect a species-specific preference
for mechanism of β-cell death and/or a disparity between modes of diabetes induction. One of these
groups later found that the low level of Fas expression in islet tissue originally reported [179] was
actually Fas expression on leukocytes, as indicated by dual staining with anti-CD45 and Fas [178].
Additionally, invading mononuclear and activated T cells stain positive for Fas activity in
immunohistochemistry studies and become apoptotic after treatment with an anti-Fas Ab, illustrating
that autoreactive cells can also be deleted by AICD during islet infiltration [171, 176, 180-182]. An in vivo
study in which IL-1β-deficient female NOD mice were used noted that spontaneous diabetes was not
significantly decreased in comparison with NOD-wt [144]. In a separate experiment, the same group
blocked IL-1β expression by creating NOD mice deficient in IL-1β-converting enzyme (ICE), which
converts the inactive IL-1β precursor to its active form. Spontaneous diabetes was again unaffected; if
Fas, whose expression is induced by IL-1β, were indeed the primary β-cell death effector, β-cell death
and diabetes induction would at least be reduced in this circumstance.
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Cell surface FasL expression ex vivo is perhaps more perplexing in that the findings are not
generally in agreement. FasL expression has been demonstrated in mice with insulitis [176, 180] but not
in the pancreas of NOD-scid/scid mice after adoptive transfer of splenocytes (data not shown) [183].
FasL is also reported to have constitutive expression in islet α-cells [181], and β-cells of Type 2 diabetic
patients [184] and non-diabetic human donors [175, 184]. However, other extant studies show FasL
expression to be present on infiltrating mononuclear cells and activated CD4+ and CD8+ lymphocytes but
not on human or mouse islet endocrine cells [131, 171, 179, 185]. One study did note the presence of
FasL transcript from diabetic pancreata preparations, but it wasn’t clear if this was β-cell specific or from
another pancreatic cell type [131].
The most commonly cited source of the general discrepancy in detection of FasL expression is
that the anti-FasL antibodies used in these studies range in their specificities for FasL, which can confer
false positive staining [171, 180, 186]. Additionally, detection of FasL could be impacted by
methodological problems such as failure to account for FasL that has been cleaved from the cell surface
or destruction of cell-surface FasL during the process of islet isolation and purification. To avoid such
problems, studies that intend to analyze β-cell FasL expression should rigorously test anti-FasL
antibodies for specificity before use and employ dual staining for FasL and insulin to localize its
expression to pancreatic β-cells.
Although ex vivo FasL studies do not conclusively establish ability for the β-cell to express FasL
mRNA or protein, it is well-established that FasL expression occurs on the surface of activated resident
and invading mononuclear cells to the islet during insulitis, as described above. This makes inducible βcell-surface Fas expression the limiting factor for potential occurrence of β-cell-immune cell Fas-FasL
interactions, and is a critical item to address for in vitro studies that require a method of cell surface Fas
induction. Incubation of primary islets or transformed insulinoma cell lines with pro-inflammatory
cytokines (e.g. IL-1β) simulates the autoimmune-mediated attack that is postulated to occur in vivo,
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since IL-1β is released from immune cells during islet infiltration. In vitro incubation with IL-1β also
appears to be a reliable method of Fas β-cell surface induction. Treatment of primary human, mouse,
and rat islets with IL-1β alone or IL-1β in combination with IFN-γ and TNF-α increases Fas mRNA
production and promotes cell surface localization in a dose-dependent manner [23, 131, 173, 177, 187189]. Expression of Fas after IL-1β treatment may depend on dose and time of exposure [179]. The
combination of IL-1β, IFN-γ, and TNF-α synergizes to enhance Fas expression, but IL-1β is likely the
dominant signal in human and murine islets [131, 179]. A similarly strong induction of cell surface Fas
expression can be obtained through treatment of non-diabetes-prone Balb/c mouse islets with IL-1α
[190]. Some studies then confirmed functionality of cytokine-induced cell surface Fas by demonstrating
an increase in apoptosis after treatment with an agonist-Fas Ab or sFasL [179, 187, 190, 191]. One group
also noted a dose-dependent increase in Fas expression after treatment of human β-cells with glucose
concentrations of up to 33.3 mmol/L [184] yet Fas expression on isolated rat β-cells was only observed
on β-cells of older (7-8 mos.) rats [192]. Furthermore, glucose-induced Fas expression on rat islets is not
enhanced by treatment with cytokines or streptozotocin treatment [193]. Interestingly, one human islet
study noted an increase in Fas transcript expression after 96 hours amongst islet cells in culture without
treatment, at comparable levels to islets treated with IL-1β, but incubation of the untreated islets with
an agonist anti-Fas Ab failed to induce apoptosis [194]. This suggests that cytokines promote Fas
accumulation at the cellular membrane leading to activation of downstream intracellular cell death
machinery [195]. Thus, isolation of islets or conditions present in culture media can potentially impact
baseline Fas expression.
Unlike that reported in primary murine islets, investigation of Fas mRNA and cell surface
expression in insulinoma cells exposed to cytokines revealed contrasting findings. RIN-5F insulinoma
cells express Fas mRNA after treatment with IL-1β, IFN-γ, and TNF-α, as well as after exposure to
streptozotocin [196]. Exposure of NOD-derived NIT-1 cells to IL-1β and IFN-γ in combination caused an
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induction of Fas cell surface expression [173, 191, 197] and total protein levels were nearly unchanged
between untreated and cytokine-treated cells, which indicates that pre-transcribed Fas protein resides
within the cell [191]; this intracellular store of Fas protein was also demonstrated in isolated islets from
diabetes-prone BB/OK rats [189]. Silencing of Fas expression by small interfering RNA (siRNA)
transfection in NIT-1 cells reduced Fas mRNA transcription by nearly 90%, and although the siRNA also
conferred a significant decrease in cell surface Fas expression, it only reduced total protein expression
after prolonged treatment [198]. This could indicate a slow turnover rate of β-cell Fas protein. C57BL/6
mouse-derived β-TC1 cells exposed to Fas siRNA demonstrated a similar but less severe phenotype than
in NIT-1 cells, in that β-TC1 cells had only a 70% decrease in Fas mRNA abundance [198]. This difference
in mechanism thus appears to not only occur within groups, but between groups as well. Whereas NIT-1
insulinoma cells can down-regulate cytokine-induced cell surface Fas after exposure to agonistic FasL,
primary NOD islets and BALB/c islets do not show this response and maintain the same level of cell
surface Fas expression with or without exposure to FasL [199].
In contrast to the above, another group treated the same NIT-1 cell line with IL-1α and IFN-γ,
which induced Fas mRNA expression but did not confer cell surface expression [190]. Further, NOD
mouse-derived MIN6N8 insulinoma cells expressed Fas mRNA in both the unstimulated and cytokinestimulated state, but Fas cell surface expression was not detected after treatment with IL-1β or IFN-γ
[185]. Additionally, treatment of the MIN6N8 cells with an agonist anti-Fas Ab did not result in
significant apoptosis, which suggests either non-functional Fas or a very low level of Fas expression.
Studies investigating β-cell-specific Fas and FasL expression have had difficulty coming to a
consensus on these criteria, in both the healthy and pathological state, for a number of reasons.
Experimental problems such as β-cell specificity in immunostaining techniques and specificity of antiFasL antibodies for FasL present easily avoidable false-positives or –negatives. But these problems
primarily surfaced because of use of separate genetic models, with this variation extending within and
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between primary islets and transformed cell lines. However, the ultimate ability of multiple groups to
demonstrate Fas cell surface expression during the natural progression of diabetes in humans and mice
was taken to mean that Fas-FasL interaction is the major mechanism of β-cell deletion.
Because NO production is required for IL-1β-mediated cytotoxicity, it could serve as a link
between cytokine exposure and β-cell surface Fas expression. However, a consensus on the requirement
of NO for induction of Fas mRNA and cell surface expression has not been reached. Exposure of iNOSdeficient murine islets to cytokines had no effect on Fas expression relative to Fas-sufficient islets [187,
200]; and although the data was not shown, one of these groups also reported that exposure of human
islets to the NOS inhibitor N-Methylarginine (NMMA) in addition to cytokines did not prevent induction
of Fas mRNA [200]. This lack of response was also replicated in NOD islet cells treated with the NMMA
and cytokines, with no significant change in Fas expression [179]. However, one of these studies
reported only a small induction of Fas expression after cytokine treatment and was already at odds with
other studies that report abundant cytokine-induced Fas expression [179]. In contrast to the above
studies, treatment of non-human primate (NHP) islet β-cells with NMMA after incubation with cytokines
resulted in attenuation of Fas expression. Additionally, treatment of NHP cells with the NO donor
sodium nitroprusside (SNP) alone induced abundant Fas expression, and exposure of primary rat islets
to cytokines after silencing iNOS expression by siRNA transfection abrogated Fas mRNA expression
[188], and together indicate that IL-1β-induced Fas expression might at least be partly dependent on the
presence of NO [131].
This controversial involvement of NO in induction of β-cell Fas expression also appears to
extend to its role in Fas-mediated β-cell death. There was little to no change in cell death among islets
from wild-type as compared with iNOS-deficient mice [187], as well as amongst mouse islets treated
with NMMA [179, 190]. One study reported an essential role for Fas in β-cell death by showing that
treatment of human islets with an anti-Fas antagonist in addition to either IL-1β or the NO donor SNP
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had no effect upon cell death [131]. However, although SNP alone was able to induce Fas expression in
NHP cells, cell death was analyzed in human islets and the ability of SNP to induce Fas expression in this
cell type had not been established. Furthermore, the link between Fas and NO would have been
strengthened had the human islets been treated with the combination of IL-1β, SNP, and anti-Fas
antagonist. Taken together, a majority of these studies indicate that NO is not required for induction of
Fas expression or Fas-mediated β-cell death. Although IL-1β has been shown by multiple groups to be
separately required for both NO and Fas expression, there appears to be no dependence for NO on Fas
expression independent of IL-1β.

Transgenic Models of T Cell-Mediated Diabetes
The TCR transgenic mouse with a rearranged TCR specific to either the CD4+ or CD8+ T cell
population is an attractive experimental model system for study of Fas-FasL interactions in β-cell death
for two fundamental reasons: 1) Although both leukocyte populations are already known to be required,
the mechanisms of CD4+ and CD8+ T cell-induced diabetes can be uncoupled from each other and
separately analyzed, with a primary focus on CD8+ CTLs due to their known role as effectors of β-cell
death [116], and 2) Transgenic mice provide a model of diabetes that is accelerated and simplified in
comparison to spontaneous diabetes, so that the T cell repertoire and direct β-cell death mediators can
be studied efficiently and without the complexities that are inherent to spontaneous diabetes [154, 163,
201, 202]. Transgenic mice can thus be used to address the autoimmune requirement and mechanism of
cell death required for T cell-mediated disease induction, neither of which has been fully elucidated.
TCR transgenic β-cell death studies are unique in that most do not solely focus on Fas-FasL
interactions as the primary death effector. As mentioned above, T cell homeostasis and CTL-mediated
target cell death are dependent on Fas-FasL interactions in addition to other death effectors, centrally
the perforin/granzyme pathway [22, 107, 108], and to a much lesser extent, the TNF/TNFR1 pathway
[203, 204]. Thus, a role for perforin in β-cell pathology leading to T1DM has also been investigated. Yet
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unlike the ambiguous role for Fas-FasL interactions, perforin/granzyme appears to have a critical role in
the effector phase of β-cell death [6, 205]. Additionally, in contrast to the initial Fas β-cell death studies
that solely addressed Fas as a β-cell death mediator, much of Fas-relevant TCR transgenic diabetes
research examines the role for Fas in addition to other relevant pathways in β-cell death and generally
acknowledges that there is more than one direct mechanism involved in β-cell death.
One of the first studies that took this approach used transgenic mice that express β-cell-surface
influenza virus hemagglutinin (HA), so the β-cells can be deleted by HA-specific CD8+ T cells extracted
from TCR-transgenic mice [161]. Both the perforin and Fas pathway were separately blocked in these
transgenic mice by use of a perforin inhibitor or by crossing the transgenic mice with the lpr/lpr
mutation, then adoptively transferring Ins-HA recipient mice with these donor CTLs. Interestingly, loss of
perforin alone caused a reduced incidence of diabetes, and loss of both pathways conferred a complete
loss of diabetes induction. However, loss of Fas expression alone had a minimal impact on diabetes
induction. Additionally, much larger numbers of perforin-deficient CTLs were required to adoptively
transfer diabetes than Fas-deficient CTLs, and mice that received perforin-deficient CTLs still stained
positive for small amounts of insulin amidst less islet infiltration than the mice that received Fasdeficient CTLs. These together indicated that perforin is the major method of β-cell cytotoxicity, but in
the absence of perforin expression, Fas-FasL interactions can cause significant cytotoxicity [161]. Two
studies published in 2006 by the same group but using separate TCR transgenic models corroborated
these results. Ovalbumin (OVA)-specific CTLs from OT-1 TCR transgenic mice can rapidly induce diabetes
upon adoptive transfer to recipients that have β-cell expression of OVA and in the absence of perforin,
β-cell killing is severely reduced. Yet absence of Fas alone has minimal effect on antigen-specific β-cell
killing, whereas perforin- and Fas-deficiency cause complete loss of antigen-specific β-cell killing [162].
Islets from NOD-lpr/lpr donors were also not protected in vivo when grafted under the kidney capsule of
mice with a rearranged TCR that is representative of the islet-specific TCR recognized by diabetogenic

35

cytotoxic CTLs (NOD8.3 mice) [163]. Additionally, NOD-wt islets were killed after treatment with CTLs
from perforin-competent NOD8.3 mice, and this killing was severely reduced when the CTLS were from
perforin-deficient NOD8.3 mice and completely abolished when NOD-lpr/lpr islets were exposed to the
perforin-deficient CTLs [163]. Finally, treatment of 7-day-old NOD mice with an antagonist anti-FasL Ab
after adoptive transfer of islet-specific CD8+ T lymphocytes did not inhibit diabetes or insulitis. However,
treatment with the anti-FasL Ab after adoptive transfer of total splenocytes from diabetic mice
conferred insulitis but not overt diabetes [151]. These results reiterate the essential role for perforin in
CD8+ T cell-mediated β-cell death, where Fas-mediated β-cell death is still possible but likely responsible
for insulitis and not the effector phase of β-cell death.
On the other hand, a separate study that also used NOD8.3 mice suggested a Fas-dependent
mechanism of β-cell death after perforin-deficient mice actually demonstrated accelerated diabetes,
and NOD8.3-CD8+ CTLs (either perforin-sufficient or -deficient) could kill Fas-sufficient but not Fasdeficient lpr/lpr NOD β-cells in vitro [206]. A third study that also used the NOD8.3 experimental mouse
model determined that perforin is required for the later stages of insulitis, whereas other perforinindependent effector mechanisms are used in the early stages of insulitis [207]. Interestingly, although
they used the same genetic mouse model, each of the NOD8.3 studies used CD8+ T cells that recognize
separate β-cell peptides, making it difficult to draw conclusions from the combined study results since
each might confer a different mechanism of action. To further complicate matters, a CD8-mediated
transgenic model of diabetes in which mice express RIP-driven transgenes for TNF and CD80, both of
which are required for diabetes induction, indicated a possible requirement for TNF in β-cell death, yet
little to no role for perforin or Fas [202].
Studies in which CD4+ T lymphocytes carry a transgenic TCR that recognizes a specific β-cell
peptide, or CD4+-induced diabetes, are less frequently investigated than CD8+ TCR transgenic studies.
Like CD8+ CTLs, CD4+ T cells are capable of β-cell cytotoxicity, as evidenced by their ability to kill Jurkat
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cells in vitro, and can also express FasL upon activation [151]. Although these activated FasL+ T cells can
kill NOD-scid/scid islets after IL-1α treatment to induce islet Fas expression, exposure to an anti-FasL Ab
can’t decrease this death; additionally, treatment of NOD-lpr/lpr islets with the same T cell clones can be
killed as efficiently as wild-type mice [151]. Cre-loxP is the term for a method of site-specific deletion of
a gene of interest (in this case Fas receptor) [208], and can be driven by the RIP to confer β-cell specific
Fas deletion (RIP-Cre+Fasfl/fl). This abrogates the lymphoid abnormalities associated with the systemic
lpr/lpr mutation and makes it an ideal model system for generating tissue-specific deletion of a given
molecule. Adoptive transfer of TCR-HA-CD4+ T cells into mice with a Cre-loxP Fas deletion had little
difference in diabetes development relative to their Fas-sufficient counterparts. Furthermore, there was
actually an accelerated rate of diabetes development in these Fas-deficient mice when induced to
diabetes with CY [153]. Additionally, in a transgenic model of diabetes in which the T cell repertoire is
composed of rearranged TCR genes from a CD4+ T cell clone (BDC2.5/NOD), Fas-deficient mice carrying
the lpr/lpr mutation still developed insulitis and only a small proportion developed diabetes after
treatment with CY [154]. Although this could be interpreted as an essential role for Fas in the
BDC2.5/NOD mouse model, T cells transferred from BDC2.5/NOD-lpr/lpr mice to BDC2.5/NOD-wt mice
had difficulty with proliferation; thus, like non-transgenic NOD-lpr/lpr mice, the decreased incidence of
diabetes in BDC2.5/NOD-lpr/lpr is likely due to alterations in the T cell repertoire and not directly due to
a Fas deficiency in the target tissue.
In stark contrast to the above, incubation of IL-1α- and IFN-ϒ-treated NOD β-cells with a CD4+
clone that can differentiate into a CTL and expresses a highly diabetogenic TCR (4.1-CD4+ CTL) results in
killing that is likely Fas-mediated, since this killing was abrogated when the islets were made Fasdeficient by the NOD-lpr/lpr mutation [145]. In vivo, the 4.1-NOD.lpr/lpr mouse developed insulitis but
not diabetes, unlike the wild-type NOD-lpr/lpr mouse, which develops neither insulitis nor diabetes;
these results indicate that in this transgenic model Fas may be necessary for the effector phase but not
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the initiation phase, whereas in the spontaneous model Fas may be responsible for the initiation phase
of β-cell death [145]. These findings were corroborated when adoptive transfer of islet-specific CD4+ T
cell clones (YNK7.3) into NOD mice, along with administration of an anti-FasL Ab, still conferred insulitis
but significantly decreased diabetes incidence, yet when the recipient mice carried the lpr/lpr mutation
insulitis was also significantly decreased [151]. In the same 4.1-NOD mouse model, another group
showed that an IL-1R antagonist did not block induction of β-cell Fas expression, and indicates that IL-1β
does not participate in upregulation of Fas expression in this particular diabetes model. These mice also
appear to be capable of Fas-independent β-cell death, as demonstrated when NOD-lpr/lpr islets grafted
into NOD4.1 mice were destroyed [147]. In contrast to these results, NOD mice infected with a
replication-deficient adenovirus for an IL-1R antagonist protein protected the islets from activation of a
protein known to be stimulated during Fas-mediated apoptosis after treatment of the islets with IL-1β
and an agonist Ab for Fas. However, the possibility exists that this marker is not stimulated during
inflammation-mediated cell death and other measures of protection from Fas-mediated cell death
would have verified these results [146].
Interestingly, one group that found little to no Fas expression on islet endocrine cells of
spontaneously diabetic NOD mice after cytokine stimulation [179] did note Fas expression on β-cells of
TCR transgenic models of diabetes [178]. They theorized that this contrast might be due to β-cell
expression of certain endogenous inhibitors of Fas, such as suppressor of cytokine signaling-1 (SOCS-1)
or an IL-1R antagonist. SOCS-1 has also received attention in some TCR transgenic mouse models due to
this characteristic and its ability to provide a level of protection against diabetes induction by preventing
the action of multiple cytokines via blocking the Jak-STAT signaling pathway [209] and hence, Fas cellsurface induction. Indeed, SOCS-1 was expressed in NOD mouse islets deficient in Fas expression
beginning at an age when they would be developing diabetes [178], and β-cell death and diabetes onset
were prevented when SOCS-1 was overexpressed in β-cells of the NOD8.3 mouse model (RIP-SOCS1-
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.NOD8.3) of CD8+-mediated diabetes [157, 163]. But this protection was perforin-dependent and Fasindependent, as seen when NOD-lpr/lpr islets overexpressing SOCS-1 were killed by 8.3 CTLS but
perforin-deficient islets were not [163], and when NOD4.1 mice overexpressing SOCS-1 did not show an
induction of β-cell Fas expression yet still developed diabetes [147]. Additionally, OVA-pulsed islets from
B6.RIP-SOCS-1 were killed by OT-1 CTLs at a comparable level to wild-type B6 islets, but perforindeficient OT-1 CTLs couldn’t kill the SOCS-1-protected islets [162]. These findings also corroborate the
results from some transgenic models of CD8+-mediated diabetes, and together indicate a majorly
perforin-dependent mechanism of β-cell death.

Intracellular Pathway of Fas-Mediated β-Cell Death
Under the assumption that β-cell death is dependent upon the presence of Fas-FasL signaling,
some groups moved to begin deducing the intracellular components required for occurrence of Fasmediated β-cell death. Although the intracellular pathway of Fas-mediated death has been largely
defined in some tissues, centrally those of hematopoietic origin, available data in the context of the
pancreatic β-cell is severely limited. Furthermore, the processes of cytokine-mediated β-cell death and
Fas-mediated β-cell death are often uncoupled from each other under the premise that cytokines can
mediate β-cell death directly by binding to cytokine receptors on the β-cell surface or indirectly, by
inducing cell surface expression of death effectors such as Fas or perforin. Some studies have indicated
separate intracellular mechanisms of death for cytokine-mediated and Fas-mediated β-cell death [210],
which seems to be paradoxical since induction of cell-surface Fas requires β-cell exposure to cytokines.
For the purposes of this review, however, the discussion will be limited to the intracellular components
required for Fas-mediated β-cell death.
Within the rat Fas promoter, an IL-1β-responsive region was determined to be between
nucleotides -223 and -54 [211]. The transcription factors nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) and CCAAT-enhancer-binding protein (C/EBP) are found within the IL-1β39

responsive sequence at nucleotide -142 and -130 respectively, and both were determined to be critical
to the Fas IL-1β response, as mutation of either alone causes a loss in expression normally induced by IL1β [211].
The responsiveness of the Fas promoter to IL-1β ultimately results in cell surface induction of
Fas receptor. As reviewed above (Figure 2), subsequent association of the FADD adaptor protein
precedes oligomerization and activation of caspase-8. Indeed, this progression also occurs in the β-cell,
where a β-cell-specific dominant-negative FADD (RIP-dnFADD) lacks a death effector domain and
competitively inhibits binding of endogenous FADD to the death domain of Fas, which would ultimately
prevent activation of the downstream components in this death pathway [148]. In vitro treatment of
NOD-RIP-dnFADD islet cells with IL-1β + IFN-ϒ + FasL conferred resistance to cell death, whereas wildtype controls were sensitive to cell death after these treatments. Additionally, diabetes incidence of
homozygous RIP-dnFADD mice was slightly reduced as compared with NOD-wt control mice, and
indicates a role, albeit minor, for Fas-FasL signaling in β-cell death [148]. These results also were
corroborated in vitro, whereby blocking FADD activity in NIT-1 cells leads to a significant but not
complete protection from cell lysis [212].
Just downstream of the FADD, initiator caspase-8 activity also appears to be required; however,
evidence for the critical role of caspase-8 in Fas-mediated β-cell death is derived from islets of human
Type 2 diabetic islets, so should be cautiously translated to the Type 1 diabetic circumstance. As
indicated above, in vitro islet exposure to glucose can induce Fas cell surface expression [184]. FLICE-like
inhibitory protein (FLIP), an endogenous protein that competitively inhibits caspase-8 by its structural
similarity and lack of proteolytic activity, has decreased protein expression levels within islets from Type
2 diabetics relative to healthy controls. This decrease in FLIP after in vitro glucose exposure also has an
inverse correlation with cell surface Fas expression, where Fas expression increases as FLIP expression
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decreases [213]. Although not directly measured in the study, these data and correlations could indicate
an essential role for caspase-8 in Fas β-cell signaling.
The intrinsic mitochondrial pathway appears not to be necessary in inflammation-mediated βcell death; although required in vitro for Fas-mediated mouse islet cell death [50], NOD mice deficient in
Bid were not protected from development of spontaneous diabetes in vivo [149]. Finally, the effector
caspase-3 has been investigated by multiple groups for its potential role in Fas-dependent β-cell death.
βTC1 insulinoma cells that were transfected with human Fas cDNA (hFas/βTC1) and exposed to an
agonist anti-Fas Ab had a marked increase in caspase-3-like activity. hFas/βTC1 cells transfected with an
anti-sense knockout of caspase-3 and then treated with agonist anti-Fas also had increased survival over
control hFas/βTC1 cells that lacked the caspase-3 knockout [214]. Additionally, NIT-1 insulinoma cells
treated with IL-1β + IFN-γ + FasL showed an increase in caspase-3 like activity, as compared with NIT-1
cells treated with cytokines alone [197, 215]. Finally, βLox5 is one of few available cell lines that is
derived from adult human β-cells. When these IL-1β-resistant cells are made deficient in mitochondrial
DNA, they are still sensitive to Fas-mediated killing, which is blocked upon addition of a pan-caspase
inhibitor to the treatment. Although there was no negative control for comparison, these data indicate
that in the absence of the mitochondrial pathway, Fas-mediated β-cell death can proceed in a caspasedependent manner [210]. Although the above-mentioned elements appear to be critical for the effector
function of β-cell Fas-FasL interactions, it is still unclear if Fas plays a role in any stage of β-cell death.

IV. Effect of Fas Signaling on Healthy β-Cell Function
A large proportion of Fas literature investigates its role in AICD and a growing body of studies
analyzes its role in pathogenic β-cell death, which together and in addition to others characterizes FasFasL signaling as a mostly pro-death event. However, Fas-FasL interactions can promote survival,
regeneration, and proliferation in some tissues [216]. This idea was extended to the β-cell, where two
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groups in particular analyzed the role of Fas in both healthy and pathological β-cell function by use of
the Cre-loxP Fas deletion model [150, 155]. Schumann et al. crossed the RIP-Cre+Fasfl/fl deletion into mice
of the NOD.C57BL/6j background and reported a surprising finding in that absence of Fas signaling
impaired glucose tolerance and lowered insulin levels. They speculated on a role for Fas in β-cell
secretory function [150]. This investigation was conducted by the same group that earlier published a
study characterizing a dual role for Fas signaling in the β-cell; Fas β-cell expression was previously shown
to be induced by glucose [184], which also directs expression of the caspase-8 inhibitor FLIP [213]. A
dual role for Fas was proposed in the latter study, where increased FLIP expression promoted Fasmediated proliferation and decreased FLIP expression caused Fas signaling to promote cell death, all of
which were dependent on islet exposure to high concentrations of glucose [213]; aging was also
correlated with enhanced death in cells exposed to high glucose concentration [192]. These were
followed up by Schumann et al., who showed that transfection of INS-1E insulinoma cells or mouse islets
with FLIP promoted mRNA expression of pro-survival factors, such as PDX-1, insulin, and NF-ĸB; while
Fas separately caused similar effects in this study, the dependence on Fas for the FLIP phenotype was
not directly measured [150].
Another group, using the RIP-Cre+Fasfl/fl mice of the 129J-C57BL/6 genetic background, reported
opposing findings in that these mice had higher glucose tolerance and GSIS than their wild-type
counterparts, although both wild-type and RIP-Cre+Fasfl/fl mice had similar insulin content and total
pancreatic content [155]. Absence of Fas signaling promoted β-cell function and Fas was not required
for islet β-cell development, as has also been suggested by other groups [148]. Moreover, there was no
change in incidence of multiple low-dose streptozotocin (MLDS)-induced diabetes between wild-type
and RIP-Cre+Fasfl/fl mice, indicating that Fas-FasL signaling is not critical to MLDS-induced autoimmune
diabetes [155]. Choi et al. theorized that this disparity might result from the separate genetic
backgrounds of the mice used in both studies, which is a likely possibility. Furthermore, the method of
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diabetes induction was different in each of these studies, where Schumann et al. used mice of the
NOD.C57BL/6j background and Choi et al. induced T1DM with MLDS; however, the separate methods of
diabetes induction still wouldn’t explain the disparity between the studies in secretory function.

V. Transgenic FasL as a Means of β-Cell Protection
Whereas some groups have attempted to characterize a role for Fas-FasL interactions in β-cell
pathology, others have taken a different approach by attempting to determine if Fas-FasL can confer βcell protection by deletion of autoreactive Fas-expressing immune cells. Although the ability of islet βcells to express FasL remains controversial [131, 171, 176, 179, 180, 185], its well-characterized role in
maintaining immune privilege of some tissues [67, 68] encouraged experimentation with ectopically
expressed β-cell FasL to render the β-cell an immune-privileged site and protect it from autoimmune
destruction. Its requirement for corneal graft survival [70] also indicated FasL as a therapeutic target for
successful transplantation of organ and islet allografts. Furthermore, the possibility that animals
transgenic for FasL could essentially have an endogenous means of immunosuppression at sites that do
not naturally confer immune privilege was extraordinarily appealing [217]. However, FasL
overexpression also presents the risk of inducing cell death in any Fas-expressing cell located within
proximity of ectopic FasL.
Indeed, experimentation with mice transgenic for FasL, however, did not yield the expected
protective outcome. NOD mice that express FasL under control of either the human insulin promoter
(HIP) or RIP, conferring β-cell-specific gene expression, developed diabetes at an accelerated rate as
compared with their nontransgenic littermates [25, 139, 218, 219], and the rate of acceleration between
transgenic strains was dependent upon the baseline level of FasL expression [25, 220]. Corroborating
well with these findings, C57BL/6 mice transgenic for human FasL (hFasL) and induced to diabetes with
MLDS developed the disease at an accelerated rate relative to their non-transgenic littermates [196].
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Ectopic FasL-driven accelerated disease development was particularly evident amongst
transgenic NOD males, which develop spontaneous diabetes at a more delayed rate than female NOD
mice, but develop accelerated diabetes at a similar rate as transgenic females. This diabetes acceleration
was abolished, however, with addition of the dominant-negative lprᶜᵍ transgene. RIP-FasL- lprᶜᵍ mice
developed spontaneous diabetes at a slightly decreased rate relative to NOD-wt mice, but after adoptive
transfer of diabetogenic splenocytes into NOD-RIP-FasL mice, introduction of the lprᶜᵍ mutation was only
able to reduce diabetes incidence to levels comparable to that of wild-type mice [139], and also
indicates that Fas-independent mechanisms are employed in the adoptive transfer model of diabetes
induction. Additionally, HIP-FasL mice of a non-diabetes-prone genetic background did not develop the
accelerated spontaneous diabetes seen in NOD mice [218]. This indicates that the NOD, or diabetesprone-background, is required for the accelerated diabetes caused by ectopic FasL expression; without
chemically-induced or immune-mediated islet inflammation, Fas has no way of being induced to the βcell surface and thus ligating FasL to initiate cell death. Finally, mice virally induced to develop T1DM by
β-cell-specific expression of the nucleoprotein of lymphocytic choriomeningitis virus (RIP-LCMV) and
carrying ectopic FasL (RIP-FasL) had a significant reduction in diabetes as compared to their non-RIP-FasL
littermates [221]. Although this turned out to be due to FasL-mediated killing of autoreactive CD8+
lymphocytes, RIP-FasL mice infected with LCMV but lacking the nucleoprotein still developed diabetes.
Significantly, the LCMV virus induced β-cell Fas expression; thus, this diabetes was caused by β-cell
fratricide and exemplifies the central problem inherent to ectopically expressed β-cell FasL.
Accelerated rejection was also demonstrated amongst islets that were grafted from
transgenic donor mice and transplanted under the renal capsule of recipient mice, an outcome that
could be attained with either mFasL or sFasL [222]. In this scenario, FasL islet expression was driven by
either the rat insulin promoter or a replication-deficient adenoviral vector containing FasL cDNA
(AdFasL). In comparison with non-transgenic littermates or littermates transduced with an adenoviral
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vector lacking FasL cDNA, RIP-FasL or AdFasL islets were rapidly infiltrated and destroyed [220, 223,
224]. To corroborate these findings, diabetic NOD recipient mice transplanted under the kidney capsule
with syngeneic islets maintained normoglycemia for 7-14 days, whereas treatment with a neutralizing
anti-FasL Ab extended this period to 30 days [158]. In addition, administration of a neutralizing anti-Fas
Ab to female NOD mice at 2-4 weeks of age almost completely prevented spontaneous diabetes onset
and delayed its incidence when administered at 5-15 weeks old [151]. However, protection from
accelerated islet rejection could be attained when the islets were co-transplanted with FasL-expressing
myoblasts or testicular allografts, which may allow for continued interest in FasL as means of protection
for islet transplantation [225, 226].
Interestingly, AdFasL islets from MRL-lpr/lpr mice and their Fas-sufficient counterparts were
rejected in the same amount of time, which would suggest that FasL-expressing islets are not killed by
autocrine interaction between islet Fas and FasL [224]. In vitro, however, treatment of RIP-FasL islets
with IL-1β and IFN-γ resulted in an almost three-fold increase in cell death as compared with
nontransgenic islets and was prevented by treatment with an antagonist anti-FasL Ab, which would
suggest that cytokines upregulate β-cell Fas, hence making the cell susceptible to autocrine Fas-FasL
interaction [219, 223]. These discrepant results could be rationalized by a different mechanism of action
between RIP-FasL and AdFasL islets, but has not been conclusively determined. Finally, the genetic
background of both donor and recipient mouse appears to plays a critical role in determination of
whether an islet transplant will be successful or rejected. Whereas syngeneic grafts from nontransgenic
C57BL/6 mouse donors had very little islet graft infiltration, grafts from RIP-FasL mice had undergone
infiltration and some had already been rejected. In contrast, allogeneic grafts from both nontransgenic
and transgenic hosts were rejected [220], and indicates that the donor and recipient must be genetically
identical for successful graft transplantation but that, contrary to contributing to transplant success, islet
FasL expression promotes rejection.
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The findings in transgenic mice and FasL-expressing islet grafts bring into question the
difference in mechanism between naturally expressed ectopic FasL and transgenic FasL and why they
confer such different outcomes. FasL islet expression appears to not only provoke acceleration of
diabetes, but also is not an appropriate therapeutic target for islet grafting. Based on the herein
reported results, mice transgenic for β-cell FasL may be susceptible to autocrine Fas-FasL interaction
after FasL-mediated neutrophil recruitment and subsequent Fas β-cell-surface activity.
In opposition to transgenic β-cell Fas expression, silencing of Fas expression by siRNA technology
may be a potential route to therapy. NOD mice were significantly protected from CY-induced diabetes
when a systemic non-viral Fas siRNA was administered intravenously at the time of CY administration,
but it is not known if these mice also carried the abnormal phenotype conferred by the lpr/lpr Fas
deficiency mutation. The potential role for Fas in insulitis was reiterated when Fas siRNA was
administered to these mice during the β-cell death phase of CY-induced diabetes, where there was no
protection from diabetes [227]. This also indicates that therapies against Fas-FasL interactions might be
most effective when targeting the insulitic phase of β-cell death.

VI. Conclusion
Fas-FasL signaling is fundamental to maintenance of homeostasis in multiple tissues. Binding of
FasL to its receptor is characterized by autocrine or paracrine interaction, of which is largely determined
by the ability of the tissue in question to express the receptor, ligand, or both [8]. Any tissue that can
express cell surface Fas is vulnerable to death by ligation of FasL, and FasL expression is therefore strictly
limited to activated T and NK cells, in addition to its constitutive expression on tissues of immune
privilege. However, this concept of FasL-mediated immune privilege appears to be limited to specific
tissues, in that ectopic FasL expression on pancreatic islets actually results in accelerated diabetes
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development, in stark contrast to the intended purpose of protection from autoimmune invasion [25,
139, 218, 219].
Perhaps the most critical role for Fas signaling is in peripheral selection and maintenance of
immune homeostasis, as was revealed by the abnormal hematopoietic cell repertoire in mice with a
systemic deficiency of Fas (lpr/lpr) or FasL (gld/gld). These mice exhibited a number of abnormal
phenotypes, such as massive lymphoproliferation and accumulation of non-malignant double-negative T
cells in the spleen and lymph nodes. Following these findings, investigation into the role for Fas signaling
in β-cell death was sparked with the demonstration that mice carrying the lpr/lpr and gld/gld mutations
were completely protected from autoimmune diabetes development [24, 25, 138] and NOD-lpr/lpr mice
adoptively transferred with diabetogenic cells failed to develop diabetes, which together cast a critical
role for Fas signaling in β-cell death. However, it was soon realized that this protection from diabetes did
not result from absence of Fas signaling on the β-cell, but rather as a result of the lymphoid
abnormalities conferred by absence of Fas on the hematopoietic cell surface, and prevented the
autoimmune response required for T1DM initiation. NOD-lpr/lpr mice also express high levels of FasL,
which was likely killing adoptively transferred splenocytes before they could initiate diabetes in the
recipient mouse [137, 140]. Although Fas β-cell studies using only the systemic lpr/lpr or gld/gld
mutation are not applicable to determining its role in β-cell pathology, interest in Fas as a β-cell death
effector lingered with the demonstration that pro-inflammatory cytokines, namely IL-1β, induced mRNA
and cell-surface β-cell Fas expression [23] and that β-cells isolated from newly-diagnosed diabetes
patients had abundant β-cell-surface Fas expression [131, 171]. However, the multiple genetic
backgrounds comprising the in vivo and in vitro Fas β-cell death research, in combination with numerous
mutations and manipulations, have resulted in a convoluted and unclear role for Fas signaling in β-cell
death.
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There exists a broad repertoire of studies that have concluded some role for Fas signaling in βcell death. Although the extent of its role varies between studies, there seems to be a general consensus
that more than one death effector participate in β-cell death, and confers both Fas-dependent and Fasindependent mechanisms of death. For example, sublethally irradiated NOD-scid/scid-lpr/lpr mice
reconstituted with diabetogenic spleen cells had a significant reduction in diabetes incidence relative to
NOD-scid/scid counterparts that were sufficient in Fas; this suggests a Fas-dependent mechanism of
disease development. However, a level of disease development still occurred in the Fas-deficient mice,
which also suggests Fas-independent T1DM development [138, 139]. TCR transgenic mouse with a
rearranged TCR specific to the CD8+ T cell population, conferring CD8+-mediated diabetes, found that
the perforin/granzyme signaling pathway comprises the major effector in β-cell death, but in the
absence of perforin, Fas signaling is also capable of executing β-cell death [161-163]. Also in CD8+ and
one model of CD4+ transgenic mice, there were reports that the Fas signaling pathway is responsible for
the initiation phase of β-cell death, whereas the perforin/granzyme pathway is responsible for the
effector phase [145, 151]. Furthermore, one of the first studies that analyzed the contribution of
perforin/granzyme to β-cell death found that perforin-deficient mice developed insulitis but not overt
diabetes, supporting this role for Fas in the initiation phase of diabetes development [6]. These findings
were also maintained by a study in which female NOD mice administered with a neutralizing anti-Fas Ab
at 2-4 weeks old were almost completely protected from spontaneous diabetes, and when administered
at 5-15 weeks they had a delayed incidence. In contrast, when the neutralizing Ab was administered at a
later time when β-cell death was occurring, diabetes incidence was unaffected [151]. Together, these
findings strongly suggest that the perforin/granzyme signaling pathway comprises the effector phase of
β-cell death, and that Fas signaling is likely responsible for the initiation phase of this process.
Contrary to the above, however, a significant proportion of Fas β-cell research has indicated that
β-cell death and development of T1DM are completely independent of Fas signaling. NOD-scid/scid-
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gld/gld mice reconstituted with wild-type splenocytes did not develop diabetes even though the
recipients were Fas-sufficient and the adoptively transferred splenocytes were FasL-sufficient [141].
NOD mice deficient in IL-1β and thus unable to induce Fas to the β-cell surface also did not have
decreased diabetes incidence relative to NOD-wt littermates [144]. Further, an in vitro model of
transgenic CD4+-induced diabetes revealed that treatment of NOD-lpr/lpr islets with the CD4+ T cell
clones elicited a similar killing efficiency as NOD-wt islets [151]. β-cell-specific deletion of Fas gene (RIPCre+Fasfl/fl) on the 129J-C57BL/6 mouse genetic background did not confer any protection from diabetes
induced with MLDS relative to their Fas-sufficient counterparts [155]. These more recent results from a
highly tissue-specific model diminish the likelihood of a critical role for Fas signaling during autoimmunemediated β-cell death. Moreover, diabetes incidence was not affected upon injection of a neutralizing
anti-FasL Ab after disease induction with either CY or adoptive transfer of diabetogenic splenocytes
[152]. It does, however, bear mention that blocking the Fas pathway in the early stages of CY-triggered
diabetes prevents diabetes incidence [143], not by blocking Fas β-cell signaling, but likely by preventing
the T cell deletion that CY should confer [152, 228].
Nevertheless, Fas might still play a critical role in development of T1DM, not through its
signaling in β-cells but from its altered signaling in the hematopoietic cellular population, which could
result in dysfunctional AICD of autoreactive T lymphocytes localized to the pancreatic islet [229]. Indeed,
newly-diagnosed diabetes patients have significantly decreased Fas expression on the surface of T and B
cells relative to healthy controls [230] and T lymphocytes from NOD mice have demonstrated a
resistance to AICD [231]. Also in support of this idea, treatment of NOD mice with an agonist anti-Fas Ab
conferred resistance to diabetes; immunohistochemical analysis of pancreatic samples from these
animals showed that infiltrating cells and not insulin-positive cells were being targeted by the Ab (data
not shown)[182], although how the antibody selectively targeted hematopoietic cells and not endocrine
cells is unclear. Furthermore, adoptive transfer of diabetogenic splenocytes that were pre-treated with a
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fusion protein of FasL bound to streptavidin (conferring an effective ability to induce cell death in
diabetogenic cells) into NOD female mice resulted in a significantly delayed incidence of diabetes [160].
Similar results were also demonstrated in mice injected with an AdCTLA4-FasL fusion protein, when the
mice were induced with MLDS and failed to develop diabetes; additionally, splenocytes from these mice
could not induce diabetes in syngeneic recipients [156]. Taken together, targeting the autoreactive T cell
repertoire by administration of an agonist Ab for Fas or soluble Fas ligand might be an effective
therapeutic intervention. However, the treatment would have to be specific for the target population, as
any cell that constitutively expresses Fas would be otherwise vulnerable to death, potentially resulting in
severe side effects and even death [40, 81].
Islet β-cell death studies are conducted in a wide variety of in vivo and in vitro models that
together comprise a number of genetic backgrounds, some of which are described above for
investigation of Fas-FasL signaling in β-cell death and development of T1DM. This range of model
systems can confer separate mechanisms of general function and death, as has been illustrated in the
numerous Fas β-cell death studies that are unable to come to a consensus on the role for Fas signaling in
β-cell death and T1DM development. Ultimately, the use of one single and appropriate model system
would likely diminish this disparity in reported findings. A possibility of such is the Cre-loxP
recombination system, whereby Fas is the target gene and Cre recombinase expression is driven by the
RIP to confer β-cell-specific gene deletion; this would present a simple and effective model system for
use in Fas β-cell research. Two groups have already used Cre-loxP gene targeting to analyze the role for
Fas in insulin secretion (NOD genetic background) [150] and β-cell pathology (non-NOD genetic
background) [155], but reported contrasting findings. Investigators have yet to explore β-cell pathology
using Cre-loxP gene targeting on the NOD mouse background, which would confer β-cell-specific Fas
deletion in a mouse model of spontaneous diabetes. This type of study design holds promise for the
future of Fas β-cell research.
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Finally, although the NOD mouse is an extraordinarily useful model for the study of T1DM, it
likely has a separate mechanism of β-cell death relative to humans; this is exemplified by the numerous
cures identified in the NOD mouse, of which are yet to be successfully translated to a human T1DM
patient [232]. Use of human islets for such studies may be the preferred genetic model for two
fundamental reasons: 1) Use of one genetic model for all T1DM studies might eliminate the disparity
between studies, and 2) Results from human islet studies are more likely to translate to a living human.
However, human pancreatic biopsy sampling is exceptionally difficult and costly due to the inaccessible
physiology of the pancreas. Although research into the mechanism underlying β-cell death has
progressed significantly in recent years, an ideal model system has yet to be developed that can
accurately translate experimental findings to a safe method of T1DM prevention.
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Classification of Literature Review Style
This literature review is categorized as a narrative review (vs. systematic) for the following reasons:
1. Critically analyzes and discusses the current state of a specific science topic.
2. Does not use a methodological approach in which readers could reproduce the data
reported solely by reading the review document.
3. Narrative approach summarizes relevant primary literature. See Figure 3 for method of article
selection.
4. Qualitative vs. quantitative approach.

Figure 3. Method for accumulation of articles to be investigated in literature review.
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Table 3. Compilation of Fas β-cell death-relevant search terms
and PubMed results for both primary literature and
reviews.
Fas + Islet
FasL + Islet
Fas ligand + Islet
Fas + β cell
FasL + β cell
Fas ligand + beta
cell
Fas + diabetes
FasL + diabetes
Fas ligand +
diabetes
Fas + Type 1
diabetes
FasL + Type 1
diabetes
Fas ligand + Type 1
diabetes
Fas + T cell +
diabetes
FasL + T cell +
diabetes
Fas ligand + T cell +
diabetes
Fas + T cell + T1D
FasL + T cell + T1D
Fas ligand + T cell +
T1D

All Articles
207
95
121
1630
417
729

Review
11
5
9
182
45
83

662
155
241

84
23
38

215

30

94

15

124

21

151

25

72

12

102

20

103
51
68

17
9
13
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Table 4. Compilation of CD95 β-cell death-relevant search
terms and PubMed results for both primary literature
and reviews.
CD95 + Islet
CD95L + Islet
CD95 Ligand + Islet
CD95 + β cell
CD95L + β cell
CD95 Ligand + β cell
CD95 + diabetes
CD95L + diabetes
CD95 Ligand +
diabetes
CD95 + Type 1
diabetes
CD95L + Type 1
diabetes
CD95 Ligand + Type
1 diabetes
CD95 + T cell +
diabetes
CD95L + T cell +
diabetes
CD95 Ligand + T cell
+ diabetes
CD95 + T cell + T1D
CD95L + T cell + T1D
CD95 Ligand + T cell
+ T1D

All Articles
89
101
112
808
596
668
221
206
226

Review
6
5
7
67
55
66
29
31
35

121

17

106

17

119

20

86

15

87

17

97

20
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11
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